board members

David U'Prichard, PhD 

David U'Prichard, PhD, Chairman 

Dr. David C. U'Prichard's 35-year professional career spans academic research, senior R&D leadership at two global pharmaceutical companies, biotech company leadership, venture capital, and extensive experience on the boards of public and private U.S., UK, European and Indian companies

In the last decade, Dr. U'Prichard has been a Venture Partner at Red Abbey Venture Partners, Apax Partners and Care Capital. From 1999 to 2003, he was CEO of 3-Dimensional Pharmaceuticals, which he took public in 2000 and sold to Johnson & Johnson. From 1997 to 1999, he served as Chairman of Research and Development at SmithKline Beecham. He worked for ICI/Zeneca from 1986 to 1997 as Executive Vice President and International Research Director from 1994 to 1997. While at Zeneca and SmithKline Beecham, Dr. U’Prichard oversaw the discovery and development of a number of successful drugs including Seroquel®, Accolate®, Avandia®, and Iressa®.


        Baijju R. Shah 

Baiju Shah 

Baiju R. Shah is Chief Executive Officer of BioMotiv and co-leader of The Harrington Project for Discovery & Development. He has extensive experience in supporting the launch of early-stage biomedical companies. Prior to BioMotiv, Mr. Shah was President and CEO of BioEnterprise, a partnership of Case Western Reserve University, Cleveland Clinic, Summa Health System, University Hospitals, and the BioInnovation Institute in Akron. BioEnterprise is a business formation, recruitment and acceleration initiative that directly assists client companies in securing resources and funding to support their growth, and also serves as a catalyst for major industry initiatives such as new capital sources, translational centers, and real estate projects. During Mr. Shah’s decade long tenure, the initiative assisted in the creation, recruitment, and acceleration of more than 110 bioscience companies in Cleveland that collectively attracted $1.3 Billion in new funding, primarily from venture capital and private equity sources. The initiative’s success has been recognized with several national awards and has helped establish the region as a recognized center of bioscience innovation.


Theodore Torphy, PhD

Dr. Ted Torphy brings to BioMotiv over 30 years of experience in the pharmaceutical industry with a successful record in both small-molecule and large-molecule drug discovery. In addition to his role with BioMotiv, he is a member of the Innovation Support Center of the Harrington Discovery Institute and Senior Advisor, R&D Strategy for the Cystic Fibrosis Foundation.

Prior to joining BioMotiv, Ted spent 12 years with Johnson & Johnson Pharmaceuticals.  His roles included Global Head of External Innovation & Business Models for Discovery Sciences, Vice President and Head of External Research and Early Development, and Corporate Vice President and Head of Johnson & Johnson’s Corporate Office of Science & Technology. In addition, he spent four years at Centocor, the biopharmaceutical arm of Johnson & Johnson, as Senior Vice President and Head of Discovery and Preclinical Development.  During this period SIMPONI®, STELARA® and SYLVANT® entered the Discovery portfolio.